Education
About Us
Working with TipRanks
Follow Us
Odonate (ODTC)
OTHER OTC:ODTC
ODTC Stock Chart & Stats
$150000.00
$50.00(0.29%)
At close: 4:00 PM EST
$150000.00
$50.00(0.29%)
Day’s Range― - ―
52-Week Range$136,000.00 - $176,040.00
Previous CloseN/A
Volume3.00
Average Volume (3M)0.00
Market Cap
$54.85B
Enterprise ValueN/A
Total Cash (Recent Filing)$48.20M
Total Debt (Recent Filing)$2.77M
Price to Earnings (P/E)―
Beta2.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding365,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-469.40
Price to Book (P/B)3.18K
Price to Sales (P/S)0.00
P/FCF Ratio39.33K
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ODTC FAQ
What was Odonate’s price range in the past 12 months?
Odonate lowest stock price was $136000.00 and its highest was $176040.00 in the past 12 months.
What is Odonate’s market cap?
Odonate’s market cap is $54.85B.
When is Odonate’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Odonate’s earnings last quarter?
Currently, no data Available
Is Odonate overvalued?
According to Wall Street analysts Odonate’s price is currently Overvalued.
Does Odonate pay dividends?
Odonate does not currently pay dividends.
What is Odonate’s EPS estimate?
Odonate’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Odonate have?
Odonate has 365,650 shares outstanding.
What happened to Odonate’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Odonate?
Currently, no hedge funds are holding shares in ODTC
Odonate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Odonate
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.